News | March 18, 2026
Zydus, Lupin join forces to expand access to semaglutide in India
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Subscribe To Our Newsletter & Stay Updated
